De novo CD5+ diffuse large B-cell lymphoma: Results of a detailed clinicopathological review in 120 patients

Haematologica

Volumn 93, Issue 8, 2008, Pages 1195-1202

  Yamaguchi, Motoko ^a   Nakamura, Naoya ^b   Suzuki, Ritsuro ^c   Kagami, Yoshitoyo ^d   Okamoto, Masataka ^e   Ichinohasama, Ryo ^f   Yoshino, Tadashi ^g   Suzumiya, Junji ^h   Murase, Takuhei ⁱ   Miura, Ikuo ^j   Ohshima, Koichi ^k   Nishikori, Momoko ^l   Tamaru, Jun Ichi ^m   Taniwaki, Masafumi ⁿ   Hirano, Masami ^e,o   Morishima, Yasuo ^d   Ueda, Ryuzo ^p   Shiku, Hiroshi ^a   Nakamura, Shigeo ^a  

^a MIE UNIVERSITY   (Japan)

^b TOKAI UNIVERSITY   (Japan)

^c NAGOYA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^d AICHI CANCER CENTER HOSPITAL   (Japan)

^e FUJITA HEALTH UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^f TOHOKU UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^g OKAYAMA UNIVERSITY   (Japan)

^h FUKUOKA UNIVERSITY   (Japan)

ⁱ Nishio Municipal Hospital   (Japan)

^j ST MARIANNA UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^k KURUME UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^l KYOTO UNIVERSITY   (Japan)

^m SAITAMA MEDICAL UNIVERSITY   (Japan)

ⁿ KYOTO PREFECTURAL UNIVERSITY OF MEDICINE   (Japan)

^o MEIJO UNIVERSITY   (Japan)

^p NAGOYA CITY UNIV MEDICAL SCHOOL   (Japan)

more..

Author keywords

BCL2; CD5; Central nervous system; Diffuse large B cell lymphoma; Histopathology

Indexed keywords

BCL2 RELATED PROTEIN A1;

AGED; ARTICLE; B CELL LYMPHOMA; CD5 POSITIVE DIFFUSE LARGE B CELL LYMPHOMA; CELL INFILTRATION; CENTRAL NERVOUS SYSTEM TUMOR; CONTROLLED STUDY; FEMALE; GIANT CELL; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; INCIDENCE; LARGE CELL LYMPHOMA; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE ANALYSIS; OVERALL SURVIVAL; POLYMORPHONUCLEAR CELL; PROGNOSIS; PROTEIN EXPRESSION; RETROSPECTIVE STUDY; TUMOR RECURRENCE;

AGED; ANTIGENS, CD; ANTIGENS, CD5; B-LYMPHOCYTES; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; IMMUNOPHENOTYPING; LYMPHOMA, LARGE B-CELL, DIFFUSE; MALE; MIDDLE AGED; PROGNOSIS; PROTO-ONCOGENE PROTEINS C-BCL-2; RETROSPECTIVE STUDIES; SURVIVAL ANALYSIS; VARIATION (GENETICS);

EID: 48749115803     PISSN: 03906078     EISSN: None     Source Type: Journal    
DOI: 10.3324/haematol.12810     Document Type: Article

References (44)

1. Harris NL, Jaffe ES, Stein H, Banks PM, Chan JK, Cleary ML, et al. A revised European-American classification of lymphoid neoplasms: a proposal from the International Lymphoma Study Group. Blood 1994;84:1361-92.
2. Jaffe ES, Harris NL, Stein H, Vardiman JW. World Health Organization classification of tumours. Pathology and genetics of tumours of haematopoietic and lymphoid tissues. Lyon: IARC Press, 2001.
3. Matolcsy A, Chadburn A, Knowles DM. De novo CD5-positive and Richter's syndrome-associated diffuse large B cell lymphomas are genotypically distinct. Am J Pathol 1995;147:207-16.
4. Yatabe Y, Nakamura S, Seto M, Kuroda H, Kagami Y, Suzuki R, et al. Clinicopathologic study of PRAD1/cyclin D1 overexpressing lymphoma with special reference to mantle cell lymphoma. A distinct molecular pathologic entity. Am J Surg Pathol 1996;20:1110-22.
5. Kume M, Suzuki R, Yatabe Y, Kagami Y, Miura I, Miura AB, et al. Somatic hypermutations in the VH segment of immunoglobulin genes of CD5-positive diffuse large B-cell lymphomas. Jpn J Cancer Res 1997;88:1087-93.
6. + diffuse large B-cell lymphomas express VH genes with somatic mutation. Blood 1998;91:1145-51.
7. Yamaguchi M, Ohno T, Oka K, Taniguchi M, Ito M, Kita K, et al. De novo CD5-positive diffuse large B-cell lymphoma: clinical characteristics and therapeutic outcome. Br J Haematol 1999;105:1133-9.
8. Nakamura N, Hashimoto Y, Kuze T, Tasaki K, Sasaki Y, Sato M, et al. Analysis of the immunoglobulin heavy chain gene variable region of CD5-positive diffuse large B-cell lymphoma. Lab Invest 1999;79:925-33.
9. + groups may constitute clinically relevant subtypes. Leukemia 1999;13:1441-7.
10. + diffuse large B-cell lymphomas. A heterogeneous group containing an unusual form of splenic lymphoma. Am J Clin Pathol 2000;114:523-33.
11. + diffuse large B-cell lymphoma: a clinicopathologic study of 109 patients. Blood 2002;99:815-21.
12. + diffuse large B-cell lymphomas. Cancer Res 2003;63:60-6.
13. + progenitor B cell. Blood 2003;101:699-702.
14. Karnan S, Tagawa H, Suzuki R, Suguro M, Yamaguchi M, Okamoto M, et al. Analysis of chromosomal imbalances in de novo CD5-positive diffuse large-B-cell lymphoma detected by comparative genomic hybridization. Gene Chromosomes Cancer 2004;39:77-81.
15. Tagawa H, Tsuzuki S, Suzuki R, Karnan S, Ota A, Kameoka Y, et al. Genome-wide array-based comparative genomic hybridization of diffuse large B-cell lymphoma: comparison between CD5-positive and CD5-negative cases. Cancer Res 2004;64:5948-55.
16. Tagawa H, Suguro M, Tsuzuki S, Matsuo K, Karnan S, Ohshima K, et al. Comparison of genome profiles for identification of distinct subgroups of diffuse large B-cell lymphoma. Blood 2005;106:1770-7.
17. + diffuse large B-cell lymphoma subgroup: development of a CD5 signature. Cancer Sci 2006;97:868-74.
18. Yoshioka T, Miura I, Kume M, Takahashi N, Okamoto M, Ichinohasama R, et al. Cytogenetic features of de novo CD5-positive diffuse large B-cell lymphoma: chromosome aberrations affecting 8p21 and 11q13 constitute major subgroups with different overall survival. Gene Chromosomes Cancer 2005;42:149-57.
19. Khalidi HS, Brynes RK, Browne P, Koo CH, Battifora H, Medeiros LJ. Intravascular large B-cell lymphoma: the CD5 antigen is expressed by a subset of cases. Mod Pathol 1998;11:983-8.
20. Kanda M, Suzumiya J, Ohshima K, Tamura K, Kikuchi M. Intravascular large cell lymphoma: clinicopathological, immuno-histochemical and molecular genetic studies. Leuk Lymphoma 1999;34:569-80.
21. Murase T, Yamaguchi M, Suzuki R, Okamoto M, Sato Y, Tamaru JI, et al. Intravascular large B-cell lymphoma (IVLBCL): a chnicopathologic study of 96 cases with special reference to the immunophenotypic heterogeneity of CD5. Blood 2007;109:478-85.
22. Ponzoni M, Ferreri AJ, Campo E, Facchetti F, Mazzucchelli L, Yoshino T, et al. Definition, diagnosis, and management of intravascular large B-cell lymphoma: proposals and perspectives from an international consensus meeting. J Clin Oncol 2007;25:3168-73.
23. + T-cell/histiocyte-rich large B-cell lymphoma. Mod Pathol 2002;15:1051-7.
24. + follicular lymphoma: a clinicopathologic study of three cases. Am J Clin Pathol 2002;118:589-98.
25. +diffuse large B-cell lymphomas. Am J Clin Pathol 2005;124:182-90.
26. + Burkitt lymphoma/leukemia. Am J Clin Pathol 1999;112:828-35.
27. + myeloid/natural killer cell precursor acute leukemia: a distinct hematolymphoid disease entity. Blood 1997;90:2417-28.
28. Yatabe Y, Suzuki R, Tobinai K, Matsuno Y, Ichinohasama R, Okamoto M, et al. Significance of cyclin D1 overexpression for the diagnosis of mantle cell lymphoma: a clinicopathologic comparison of cyclin D1-positive MCL and cyclin D1-negative MCL-like B-cell lymphoma. Blood 2000;95:2253-61.
29. Hermine O, Haioun C, Lepage E, d'Agay MF, Briere J, Lavignac C, et al. Prognostic significance of bcl-2 protein expression in aggressive non-Hodgkin's lymphoma. Groupe d'Etude des Lymphomes de l'Adulte (GELA). Blood 1996;87:265-72.
30. Hans CP, Weisenburger DD, Greiner TC, Gascoyne RD, Delabie J, Ott G, et al. Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray. Blood 2004;103:275-82.
31. A predictive model for aggressive non-Hodgkin's lymphoma. The International Non-Hodgkin's Lymphoma Prognostic Factors Project. N Engl J Med 1993;329:987-94.
32. Matolcsy A, Inghirami G, Knowles DM. Molecular genetic demonstration of the diverse evolution of Richter's syndrome (chronic lymphocytic leukemia and subsequent large cell lymphoma). Blood 1994;83:1363-72.
33. The World Health Organization classification of malignant lymphomas in Japan: incidence of recently recognized entities. Lymphoma Study Group of Japanese Pathologists. Pathol Int 2000;50:696-702.
34. Tamura K, Sawada H, Izumi Y, Fukuda T, Utsunomiya A, Ikeda S, et al. Chronic lymphocytic leukemia (CLL) is rare, but the proportion of T-CLL is high in Japan. Eur J Haematol 2001;67:152-7.
35. Inaba T, Shimazaki C, Sumikuma T, Okano A, Hatsuse M, Okamoto A, et al. Expression of T-cell-associated antigens in B-cell non-Hodgkin's lymphoma. Br J Haematol 2000;109:592-9.
36. Ogawa S, Yamaguchi M, Oka K, Taniguchi M, Ito M, Nishii K, et al. CD21S antigen expression in tumour cells of diffuse large B-cell lymphomas is an independent prognostic factor indicating better overall survival. Br J Haematol 2004;125:180-6.
37. Linderoth J, Jerkeman M, Cavallin-Stahl E, Kvaloy S, Torlakovic E. Immunohistochemical expression of CD23 and CD40 may identify prognostically favorable subgroups of diffuse large B-cell lymphoma: a Nordic Lymphoma Group study. Clin Cancer Res 2003;9:722-8.
38. Gary-Gouy H, Harriague J, Bismuth G, Platzer C, Schmitt C, Dalloul AH. Human CD5 promotes B-cell survival through stimulation of autocrine IL-10 production. Blood 2002;100:4537-43.
39. Mounier N, Briere J, Gisselbrecht C, Emile J-F, Lederlin P, Sebban C, et al. Rituximab plus CHOP (R-CHOP) overcomes bcl2-associated resistance to chemotherapy in elderly patients with diffuse large B-cell lymphoma (DLBCL). Blood 2003;101:4279-84.
40. Winter JN, Weller EA, Horning SJ, Krajewska M, Variakojis D, Habermann TM, et al. Prognostic significance of Bcl-6 protein expression in DLBCL treated with CHOP or R-CHOP: a prospective correlative study. Blood 2006;107:4207-13.
41. Nyman H, Adde M, Karjalainen-Lindsberg M-L, Taskinen M, Berglund M, Amini R-M, et al. Prognostic impact of immunohistochemically defined germinal center phenotype in diffuse large B-cell lymphoma patients treated with immunochemotherapy. Blood 2007;109:4930-5.
42. Hollender A, Kvaloy S, Nome O, Skovlund E, Lote K, Holte H. Central nervous system involvement following diagnosis of non-Hodgkin's lymphoma: a risk model. Ann Oncol 2002;13:1099-107.
43. Feugier P, Virion JM, Tilly H, Haioun C, Marit G, Macro M, et al. Incidence and risk factors for central nervous system occurrence in elderly patients with diffuse large-B-cell lymphoma: influence of rituximab. Ann Oncol 2004;15:129-33.
44. Tilly H, Lepage E, Coiffier B, Blanc M, Herbrecht R, Bosly A, et al. Intensive conventional chemotherapy (ACVBP regimen) compared with standard CHOP for poor-prognosis aggressive non-Hodgkin lymphoma. Blood 2003;102:4284-9.